Strontium ranelate delisted from PBS

Strontium ranelate (Protos) has been delisted from the PBS since August 1, with patients expected to pay up to $60 for a private prescription.  

The drug has been mired in controversy since 2014 when a European Medicines Agency sub-committee concluded strontium’s risk-benefit profile was “no longer favourable” and that it should not be used to treat osteoporosis.